Top Health Tech Companies With Best Stability & Growth (8,093)

Strong Revenue Growth: Recent disclosures show sustained top-line expansion across multiple quarters and fiscal years, with management raising near-term sales outlook. Growth is supported by specialty drug demand, international expansion initiatives, and contributions from acquisitions such as Retina Consultants of America and OneOncology.

Profitability: Adjusted earnings and operating income have increased, and guidance for operating income growth was raised. Margin mix benefits from specialty exposure and recent deals are cited, even as reported results include some non‑recurring items.

Strong Market Position & Advantage: The company operates within a highly concentrated U.S. distribution market as a Fortune‑scale leader with global specialty logistics and services capabilities. Multi‑year investments to expand distribution capacity and cold‑chain infrastructure reinforce competitive positioning.

Market Expansion: Market Expansion: Nationwide telehealth availability and launches into additional categories beyond obesity care indicate an expanding geographic and service footprint. Company posts and event sponsorships reinforce ongoing outreach consistent with a scale-up trajectory.

Product Line Growth: Product Line Growth: An actively updated iOS app and refreshed online platform, together with new specialty areas, show continued investment in product and service breadth. The organization appears to be evolving from a single-category clinic toward a broader digital health offering.

Strong Hiring & Retention: Strong Hiring & Retention: Frequent role postings on professional networks and visible employer-brand activity point to active headcount growth. Hiring across functions such as marketing and design suggests support capabilities are being built alongside core clinical and product teams.

Profitability: Recent results indicate high operating leverage with strong margins and cash generation even as the top line expands. Management reported robust profitability alongside growing engagement and product adoption.

Strong Revenue Growth: Fiscal results and current-year guidance point to ongoing double‑digit revenue expansion from a larger base. Quarterly performance remained year‑over‑year positive despite variability between periods.

Strong Market Position & Advantage: Company disclosures indicate reach to a large majority of U.S. physicians with record engagement across newsfeed, workflow, and AI tools. Widely used telehealth and workflow utilities reinforce defensibility with clinicians.

Profitability: Signals indicate the company returned to profitability by 2023 and maintained profitable growth into 2024–2025, reflecting increased financial stability.

Strong Market Position & Advantage: Public materials portray the firm as a category leader in U.S. consumer doctor discovery and real-time booking, operating at national scale with millions of bookings.

Strategic Partnerships: Recent integrations with organizations like Blue Shield of California, Healthgrades, Yelp, and large health systems expand distribution and reinforce platform reach.

Investor Backing & Capital Strength: Fresh capital includes a $50M Series D on April 9, 2026 led by Boehringer Ingelheim and a 2025 Series C with Dassault Systèmes/Medidata to fund commercialization and platform scaling. Feedback suggests these transactions reflect strong external confidence and provide runway to advance regulatory and launch efforts.

Product Line Growth: Multiple FDA authorizations (Rejoyn in 2024; CT‑132 in 2025), positive Phase 3 data for CT‑155, and acquisition of Better Therapeutics’ assets expand the portfolio across psychiatry, neurology, and cardiometabolic conditions. A 2026 Ultrahuman partnership further extends migraine technology into adjacent offerings.

Strategic Partnerships: Multi‑year collaborations with Boehringer Ingelheim and Otsuka, plus ecosystem ties with Dassault Systèmes/Medidata and Ultrahuman, underpin development and prospective commercialization. These alliances distribute risk and provide capabilities and channels that many peers lack.

Investor Backing & Capital Strength: A $30M Series A led by Sequoia Capital (March 5, 2025) and visible hiring/office expansion signal access to capital supporting scale. Active job postings and a larger San Francisco office with capacity for 65+ teammates reinforce ongoing investment.

Strong Revenue Growth: Independent estimates and company communications point to ARR around the high–teens to $20M range by spring 2025 with rapid year-over-year increases. Rising clinician counts (e.g., “26,000+” cited in April 2026 materials) align with this momentum.

Product Line Growth: The April 2026 launch of “Freed Front Desk” with published pricing, alongside coding, pre‑charting, templates, and EHR push features, shows expansion beyond a single scribe product. Claims of significant hold‑time reduction and broader workflow coverage indicate movement into adjacent front‑office functions.

Strong Market Position & Advantage: Company materials consistently describe the nation’s largest digital point‑of‑care network, citing roughly 30,000 physician offices and 125,000 providers. The 2021 combination with Outcome Health further established a scaled platform that the company has continued to build upon.

Product Line Growth: Two March 2026 launches—Health Audiences (programmatic buying) and the Consumer Health Network—add new monetization paths and access to additional advertiser segments. These offerings broaden routes to revenue beyond the historical core.

Investor Backing & Capital Strength: On August 25, 2025, Advent International announced a definitive agreement to acquire the company to accelerate network expansion and product innovation. Company and third‑party communications frame the deal around continued growth ambitions.

Strong Revenue Growth: Reported total net revenue rose from $693.4 million in 2024 to about $1.27 billion in 2025, with Q4 2025 also showing strong year‑over‑year growth. Management guides 2026 revenue to roughly $1.59 billion, indicating continued expansion.

Customer Loyalty & Retention: Disclosed net revenue retention of approximately 126% and total remaining contract value exceeding $1.1 billion signal expanding multi‑year demand. These metrics indicate existing customers are increasing spend and extending commitments.

Strategic Partnerships: Multi‑year collaborations with major pharmas and health systems—including a three‑year, $200 million data/modeling agreement with AstraZeneca/Pathos and an expanded Merck collaboration—support growth in data licensing and AI applications. Partnerships with top‑tier sponsors evidence strong demand for the platform.

Investor Backing & Capital Strength: Funding of a $29M Series A led by Sapphire Ventures is presented as providing resources to scale product and go-to-market. This capital raise is cited alongside ongoing hiring and expansion activities.

Product Line Growth: Launches of the 'Billie' AI agent for billing and later eligibility features, followed by the 2026 Pledge Health acquisition, are described as broadening the platform and extending automation into pre-service workflows. These moves expand the upsell surface and end-to-end coverage.

Market Expansion: Partnerships such as being named a preferred partner by CentralReach and references to use across 3,000+ facilities indicate meaningful penetration and distribution. Company communications also highlight rising daily patient engagement and active recruiting as demand signals.

Investor Backing & Capital Strength: Feedback suggests the $300 million growth investment from Vista Equity Partners in 2022 provided meaningful scale capital. Subsequent acquisitions and continued product launches indicate this capital is being deployed to expand capabilities.

Product Line Growth: Feedback suggests the portfolio broadened with CareConduit, Pre‑Hospital and Transfer solutions, and an AI‑powered Operator Console. FDA 510(k) clearance for Alarm Management and adjacent acquisitions further extend the platform’s breadth and go‑to‑market.

Strong Market Position & Advantage: Feedback suggests repeated placement as a Leader in Gartner’s CC&C Magic Quadrant and leadership across G2 categories signal sustained competitive strength and adoption. Regulatory and ecosystem credibility (e.g., FDA clearance, industry events) reinforce enterprise‑grade positioning.

Strong Revenue Growth: Recent disclosures indicate 2025 revenue surpassed $750 million with 45% year‑over‑year growth, with outlook commentary noting sales approaching $1 billion in 2026. This trajectory reflects accelerating scale across the business.

Profitability: The company reports eight consecutive years of profitability. Business press coverage reinforces this sustained profitable profile alongside rapid scaling.

Diversified Revenue Streams: Management emphasizes health services and media as incremental growth vectors, with third‑party coverage noting strong 2025 growth in both areas. Babylist Health’s first‑year traction (including large volumes of insurance‑covered breast pump shipments) underscores revenue diversity beyond core registry commerce.

Strong Revenue Growth: Company disclosures indicate scale of 1.6 million paying members and more than $700 million in annual sales by March 2025, echoed by major business coverage. Public updates also reference double‑digit year‑over‑year membership growth in Q1 2025, suggesting continued momentum.

Profitability: Company leaders indicated the first full year of profitability in 2023, positioning the business to reinvest for its next stage of growth. This milestone signals improved unit economics after earlier scaling years.

Diversified Revenue Streams: The 2024 launch of a retail media network with Instacart’s Carrot Ads adds an incremental, higher‑margin advertising channel alongside core membership commerce. Access and product expansions, including SNAP EBT acceptance and frozen assortment growth, further broaden monetization paths.

Strong Revenue Growth: Company disclosures indicate recurring revenue rose significantly in recent periods and the customer base expanded from thousands to many thousands across North America. Growth is further evidenced by enterprise adoption and continued product and market launches.

Market Expansion: The company has moved beyond offices into hospitality, multi-family, factories, warehouses, gyms, and airport lounges, opened a new direct market, and entered the U.K. and Ireland. These steps show widening geographic reach and vertical diversification.

Profitability: Leadership states the business achieved profitability and expects EBITDA positivity, implying improving unit economics alongside scale. This profitability is presented alongside continued hiring and product development.

Investor Backing & Capital Strength: Successive raises since 2024, including a recently reported $65M round in March 2026, indicate strong access to capital to fund product and go‑to‑market expansion.

Market Expansion: EHR integrations covering a large share of senior living (ALIS/ECP/Yardi live with PointClickCare and August Health on the roadmap) and references to deployments across hundreds of communities signal widening distribution and access to customers.

Innovation-Driven Growth: An expanding platform (Sage Core, Detect, Insight) and new workflow features suggest product breadth and AI‑enabled capabilities that support differentiated growth beyond point solutions.

Product Line Growth: The company rebranded to Intellistack and launched the AI‑native Streamline platform with a CLM module, maintaining monthly feature releases into early 2026. This broadens scope beyond legacy forms/doc/e‑sign into end‑to‑end workflow orchestration.

Market Expansion: Positioning highlights large enterprise and regulated customers (e.g., healthcare) and Salesforce‑centric workflows, alongside a new Healthcare Advisory Board and invitations for increased SI investment in 2026. These moves indicate an up‑market push and deeper focus in priority verticals.

Investor Backing & Capital Strength: Backing from PSG Equity and Silversmith Capital Partners, including a $425M growth investment announced in 2021, provides resources to fund product and go‑to‑market initiatives. Continued operation of Formstack/Formsite alongside Streamline signals capacity to support expansion.

Strong Revenue Growth: Recent disclosures cite surpassing $1 billion in 2023 and approximately $1.1 billion in 2024, with double‑digit momentum into the first half of 2024. These signals point to sustained top‑line expansion beyond the initial $1B milestone.

Product Line Growth: Frequent IRIS releases through 2025 (e.g., 2025.3) and new offerings such as IntelliCare EHR, Payer Connector, and HealthShare AI Assistant indicate an expanding portfolio. Added capabilities like vector support and enhanced partitioning underscore continued product investment.

Strong Brand Reputation: Multiple 2025–2026 Best in KLAS awards and IDC MarketScape leadership placements reinforce category strength in healthcare. Repeated honors for Acute Care EHR in Asia/Oceania/France and Shared Care Records in Europe suggest durable customer trust.

Investor Backing & Capital Strength: Feedback suggests substantial late-stage funding from prominent investors and a rising valuation underpin resources for expansion and product development. These signals point to strong capital availability to support scaling plans.

Strong Market Position & Advantage: Feedback suggests adoption by many top MedTech companies and industry recognition indicate an advantaged position within its defined niche. Case studies and enterprise expansions further reinforce perceived market traction.

Innovation-Driven Growth: Feedback suggests ongoing AI feature releases, product enhancements, and ecosystem integrations are catalyzing customer adoption. These moves demonstrate a roadmap focused on modernizing MedTech commercial workflows.

Investor Backing & Capital Strength: Recent financing at a sharply higher valuation, including strategic healthcare investors, signals strong external confidence and ample resources for scale. Management’s stated expansion plans and partnerships indicate capital is being deployed toward R&D and international growth.

Strong Revenue Growth: Company-reported bookings grew significantly year over year and aligned third‑party estimates indicate an exit run rate around the billion‑dollar level. These signals point to robust top‑line momentum heading into 2026.

Healthy Cash Flow: Management reported operating cash‑flow positivity in 2025. Positive cash generation alongside growth supports increased operating flexibility.

Market Expansion: Public materials and profiles indicate adoption has grown to cover a majority of U.S. clinics between 2022 and 2024, pointing to continued penetration across the domestic market.

Product Line Growth: The platform has expanded beyond procurement into a Home Delivery pharmacy and is rolling out integrations with major practice‑management systems, broadening its operational footprint.

Strategic Partnerships: Industry and association pages show Vetcove listed as a member benefit and purchasing channel alongside major distributors and manufacturers, indicating broad partner presence.

Strong Market Position & Advantage: Independent rankings and neutral trade coverage consistently position Waystar as a category leader in claims/clearinghouse and patient access. Scale indicators and product breadth further reinforce this standing.

Strong Revenue Growth: Recent results show growth in 2025 with guidance pointing to continued expansion into 2026. Record bookings, a large pipeline, and backlog provide near-term visibility.

Investor Backing & Capital Strength: The 2024 IPO raised substantial capital, strengthening the balance sheet to fund expansion. Management underscores investment capacity to accelerate AI-enabled workflows and platform breadth.